CNS drug development perspectives for young neurologists | 48267

Journal of Neurology & Neurophysiology

ISSN - 2155-9562

CNS drug development perspectives for young neurologists

3rd International Conference and Exhibition on Neurology & Therapeutics

September 08-10, 2014 Hilton Philadelphia Airport, USA

Marie Trad

Special Session: J Neurol Neurophysiol

Abstract :

The role of Neurologists participating in drug development activities has increased quite significantly in the past 15 years. The CNS drug market is one of the largest with many indications lacking effective therapy. With the increase of life-expectancy, the burden of neurological diseases will expand notably in the coming years. Participating actively, in bringing to the patients, therapies for conditions with unmet medical needs, is very rewarding for the clinical research neurologist, regardless the challenges. The pharmaceutical industry need for specialized medical staff, with clinical experience, is expanding rapidly. Perspectives for young neurologists wishing to take part in this exciting journey include careers in: Clinical Pharamacology, phase II/III clinical research and development, medical affairs, safety and pharmacovigilance, medical education and communication, regulatory affairs, medical writing, strategy and consultancy. Work opportunities in big pharma companies, Biotechs, CROs and independent consultancy practices, can be considered for neurologists wishing to integrate the drug development field.

Biography :

Marie Trad is an Executive Medical Director, acting currently as the Medical and Scientific Drug Development lead in Neurosciences within the CNS Therapeutic Delivery Unit at Quintiles. Trad is a board certified Neurologist and qualified Neuroradiologist from the Pierre and Marie Curie University of Paris, France. She has over 25 years of CNS experience of which 11 years as a clinical Neurologist/Neuroradiologist and 14 years of pharmaceutical industry, focusing on clinical trial management, providing medical, clinical and global strategic support related to Neurology and Psychiatry trials.